VivoSeq
Infectious Disease

Cytomegalovirus (CMV)

0

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Cytomegalovirus (CMV) is an early-stage landscape with 0 programs across 8 companies. The most active players are Moderna, Roche, GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalIonis Pharmaceuticals logo

Ionis Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

38

clinical trials

Completed30 · 79%
Unknown status3 · 8%
Withdrawn3 · 8%
Terminated1 · 3%
Recruiting1 · 3%

Clinical Trials

Trial Activity

38 trials

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Recruiting·NNew York Medical College·Phase 2·NCT03266640·20 enrolled
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
Completed·GSK logoGSK·N/A·NCT01357915·47 enrolled
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05099965·90 enrolled
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
Completed·UUniversity College, London·Phase 4·NCT00947141·165 enrolled
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02210065·6 enrolled
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients
Completed·HHadassah Medical Organization·Phase 3·NCT00284687·20 enrolled
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
Completed·Moderna logoModerna·Phase 2·NCT04975893·135 enrolled
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
Completed·Gilead logoGilead·Phase 2·NCT00002437·48 enrolled
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
Completed·MMilton S. Hershey Medical Center·Phase 1·NCT00673868·2 enrolled
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Completed·TThe George Washington University Biostatistics Center·Phase 3·NCT01376778·399 enrolled
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT03840174·18 enrolled
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Completed·Moderna logoModerna·Phase 2·NCT04232280·315 enrolled
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Completed·Roche logoRoche·Phase 3·NCT00002377
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·N/A·NCT00002355·60 enrolled
The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000989·50 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)